Last reviewed · How we verify
CIC Vaccine with Matrix-M Adjuvant
The CIC vaccine with Matrix-M adjuvant works by stimulating the body's immune system to produce a protective response against the COVID-19 virus.
The CIC vaccine with Matrix-M adjuvant works by stimulating the body's immune system to produce a protective response against the COVID-19 virus. Used for COVID-19 prevention.
At a glance
| Generic name | CIC Vaccine with Matrix-M Adjuvant |
|---|---|
| Sponsor | Novavax |
| Drug class | vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This vaccine uses a piece of the SARS-CoV-2 virus, known as a spike protein, to trigger an immune response. The Matrix-M adjuvant helps to enhance this response, allowing the body to produce more antibodies and immune cells to fight the virus.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- Lot Consistency Study of COVID-19 and Influenza Combination Vaccine (PHASE2, PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CIC Vaccine with Matrix-M Adjuvant CI brief — competitive landscape report
- CIC Vaccine with Matrix-M Adjuvant updates RSS · CI watch RSS
- Novavax portfolio CI